Patents by Inventor Douglas Covey

Douglas Covey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEUROSTEROIDS AND ENANTIOMERS THEREOF FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE CONDITIONS
    Publication number: 20240041898
    Abstract: The present disclosure is directed to a composition for prevention or treatment of neurodegenerative conditions. The composition comprises a neurosteroid, a synthetic enantiomer of a neurosteroid, or a combination thereof.
    Type: Application
    Filed: October 13, 2022
    Publication date: February 8, 2024
    Inventors: Douglas Covey, Charles Zorumski, Yukitoshi Izumi, Makoto Ishikawa
  • NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME
    Publication number: 20230190770
    Abstract: The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: February 9, 2023
    Publication date: June 22, 2023
    Inventors: Douglas Covey, Albert Jean Robichaud
  • NEUROSTEROIDS AND ENANTIOMERS THEREOF FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE CONDITIONS
    Publication number: 20230058339
    Abstract: The present disclosure is directed to a composition for prevention or treatment of neurodegenerative conditions. The composition comprises a neurosteroid, a synthetic enantiomer of a neurosteroid, or a combination thereof.
    Type: Application
    Filed: October 13, 2022
    Publication date: February 23, 2023
    Inventors: Douglas Covey, Charles Zorumski, Yukitoshi Izumi, Makoto Ishikawa
  • NMDAR INHIBITING AGENTS AND GABAAR POTENTIATING AGENTS AND USES THEREOF
    Publication number: 20220396597
    Abstract: N-methyl-d-aspartate receptors (NMDAR) and/or potentiating y-aminobutyric acid receptors (GABAAR) agents and uses thereof are described. Uses of these agents include methods of treating or preventing various psychiatric diseases, disorders, or conditions and methods of treating or preventing alcohol use disorder in a subject in need thereof.
    Type: Application
    Filed: October 16, 2020
    Publication date: December 15, 2022
    Applicant: Washington University
    Inventors: Douglas Covey, Steven Mennerick
  • Neurosteroids and enantiomers thereof for the prevention and treatment of neurodegenerative conditions
    Patent number: 11497754
    Abstract: The present disclosure is directed to a composition for prevention or treatment of neurodegenerative conditions. The composition comprises a neurosteroid, a synthetic enantiomer of a neurosteroid, or a combination thereof.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: November 15, 2022
    Assignee: Washington University
    Inventors: Douglas Covey, Charles Zorumski, Yukitoshi Izumi, Makoto Ishikawa
  • NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME
    Publication number: 20210308149
    Abstract: The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: June 21, 2021
    Publication date: October 7, 2021
    Inventors: Douglas Covey, Albert Jean Robichaud
  • NEUROSTEROIDS AND ENANTIOMERS THEREOF FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE CONDITIONS
    Publication number: 20200246356
    Abstract: The present disclosure is directed to a composition for prevention or treatment of neurodegenerative conditions. The composition comprises a neurosteroid, a synthetic enantiomer of a neurosteroid, or a combination thereof.
    Type: Application
    Filed: February 5, 2020
    Publication date: August 6, 2020
    Applicant: Washington University
    Inventors: Douglas Covey, Charles Zorumski, Yukitoshi Izumi, Makoto Ishikawa
  • NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME
    Publication number: 20200113916
    Abstract: The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: May 22, 2019
    Publication date: April 16, 2020
    Inventors: Douglas Covey, Albert Jean Robichaud
  • Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
    Patent number: 10342809
    Abstract: The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: July 9, 2019
    Assignees: Washington University, Sage Therapeutics, Inc.
    Inventors: Douglas Covey, Albert Jean Robichaud
  • Neuroactive enantiomeric 15-, 16- and 17-substituted steroids as modulators for GABA type-A receptors
    Patent number: 10202413
    Abstract: The present disclosure is generally directed to neuroactive enantiomeric 15-, 16- and 17-substituted steroids with additional optional substituents at carbons 3, 4, 6, 7, 10 and 13, and pharmaceutically acceptable salts thereof, for use as, for example, modulators for GABA type-A receptors. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: February 12, 2019
    Assignee: Washington University
    Inventor: Douglas Covey
  • Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
    Patent number: 10160783
    Abstract: The present disclosure is generally directed to neuroactive 13, 17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: December 25, 2018
    Assignee: Washington University
    Inventors: Douglas Covey, Xin Jiang
  • Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
    Patent number: 10160738
    Abstract: The present disclosure is generally directed to neuroactive substituted cyclopent[a]anthracenes as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: December 25, 2018
    Assignee: Washington University
    Inventor: Douglas Covey
  • NEUROACTIVE SUBSTITUTED CYCLOPENT[a]ANTHRACENES AS MODULATORS FOR GABA TYPE-A RECEPTORS
    Publication number: 20180086727
    Abstract: The present disclosure is generally directed to neuroactive substituted cyclopent[a]anthracenes as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: December 13, 2016
    Publication date: March 29, 2018
    Inventor: Douglas Covey
  • NEUROACTIVE 13, 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS
    Publication number: 20170355728
    Abstract: The present disclosure is generally directed to neuroactive 13, 17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: October 25, 2016
    Publication date: December 14, 2017
    Inventors: Douglas Covey, Xin Jiang
  • NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME
    Publication number: 20170232006
    Abstract: The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: May 4, 2017
    Publication date: August 17, 2017
    Inventors: Douglas Covey, Albert Jean Robichaud
  • NEUROACTIVE SUBSTITUTED CYCLOPENT[a]ANTHRACENES AS MODULATORS FOR GABA TYPE-A RECEPTORS
    Publication number: 20170233356
    Abstract: The present disclosure is generally directed to neuroactive substituted cyclopent[a]anthracenes as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: December 13, 2016
    Publication date: August 17, 2017
    Inventor: Douglas Covey
  • NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME
    Publication number: 20170190732
    Abstract: The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: March 15, 2017
    Publication date: July 6, 2017
    Inventors: Douglas Covey, Albert Jean Robichaud
  • Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
    Patent number: 9676812
    Abstract: The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: June 13, 2017
    Assignees: Washington University, Sage Therapeutics, Inc.
    Inventors: Douglas Covey, Albert Jean Robichaud
  • NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME
    Publication number: 20170152282
    Abstract: The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 1, 2017
    Applicant: Washington University
    Inventors: Douglas Covey, Albert Jean Robichaud
  • Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
    Patent number: 9630986
    Abstract: The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: April 25, 2017
    Assignees: Washington University, Sage Therapeutics, Inc.
    Inventors: Douglas Covey, Albert Jean Robichaud